Do analysts rate PLUR or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PLUR or BRTX?

In the previous week, Biorestorative Therapies had 1 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Biorestorative Therapies and 2 mentions for Pluri. Pluri's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SYBX or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SYBX or BRTX?

In the previous week, Biorestorative Therapies had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BRTX or HIND?

Vyome has a consensus price target of $9.25, suggesting a potential upside of 349.03%. Given Vyome's stronger consensus rating and higher probable upside, analysts clearly believe Vyome is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts prefer BRTX or LSTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to BRTX or LSTA?

In the previous week, Lisata Therapeutics had 3 more articles in the media than Biorestorative Therapies. MarketBeat recorded 6 mentions for Lisata Therapeutics and 3 mentions for Biorestorative Therapies. Lisata Therapeutics' average media sentiment score of 0.40 beat Biorestorative Therapies' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BRTX or NRSN?

NeuroSense Therapeutics has a consensus price target of $170.00, suggesting a potential upside of 2,197.30%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Biorestorative Therapies (BRTX) Competitors

$2.51 -0.09 (-3.46%)

Closing price 09/24/2026 03:59 PM Eastern

Extended Trading

$2.49 -0.02 (-0.72%)

As of 09/24/2026 08:00 PM Eastern

Compare

BRTX vs. PLUR, SYBX, HIND, LSTA, and NRSN

Should you buy Biorestorative Therapies stock or one of its competitors? Biorestorative Therapies's main competitors and comparable companies include Pluri (PLUR), Synlogic (SYBX), Vyome (HIND), Lisata Therapeutics (LSTA), and NeuroSense Therapeutics (NRSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biorestorative Therapies compare to Pluri?

Pluri (NASDAQ:PLUR) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

16.6% of Pluri shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pluri has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Biorestorative Therapies had 1 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Biorestorative Therapies and 2 mentions for Pluri. Pluri's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pluri has a net margin of -2,344.59% compared to Biorestorative Therapies' net margin of -3,088.27%. Pluri's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biorestorative Therapies has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	12.71	-$23.82M	-$2.45	N/A
Biorestorative Therapies	$360K	9.62	-$14.24M	-$21.40	N/A

Summary

Pluri beats Biorestorative Therapies on 7 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Synlogic?

Synlogic (NASDAQ:SYBX) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Biorestorative Therapies has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,745.48	-$23.36M	-$0.06	N/A
Biorestorative Therapies	$360K	9.62	-$14.24M	-$21.40	N/A

Synlogic has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biorestorative Therapies had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Synlogic has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Synlogic's return on equity of -26.47% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 2.6% of Synlogic shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biorestorative Therapies beats Synlogic on 7 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Vyome?

Biorestorative Therapies (NASDAQ:BRTX) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Vyome has lower revenue, but higher earnings than Biorestorative Therapies. Vyome is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	9.62	-$14.24M	-$21.40	N/A
Vyome	$320K	45.19	-$10.26M	-$3.37	N/A

Vyome has a consensus price target of $9.25, suggesting a potential upside of 349.03%. Given Vyome's stronger consensus rating and higher probable upside, analysts clearly believe Vyome is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Biorestorative Therapies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Vyome has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 33.0% of Vyome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biorestorative Therapies had 1 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Biorestorative Therapies and 2 mentions for Vyome. Biorestorative Therapies' average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Vyome	Neutral

Vyome has a net margin of -3,024.84% compared to Biorestorative Therapies' net margin of -3,088.27%. Vyome's return on equity of -197.33% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Vyome	-3,024.84%	-197.33%	-138.14%

Summary

Vyome beats Biorestorative Therapies on 11 of the 15 factors compared between the two stocks.

How does Biorestorative Therapies compare to Lisata Therapeutics?

Biorestorative Therapies (NASDAQ:BRTX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Biorestorative Therapies has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Lisata Therapeutics had 3 more articles in the media than Biorestorative Therapies. MarketBeat recorded 6 mentions for Lisata Therapeutics and 3 mentions for Biorestorative Therapies. Lisata Therapeutics' average media sentiment score of 0.40 beat Biorestorative Therapies' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Biorestorative Therapies has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	9.62	-$14.24M	-$21.40	N/A
Lisata Therapeutics	$170K	79.50	-$16.59M	-$1.64	N/A

Lisata Therapeutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Lisata Therapeutics' return on equity of -116.08% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Lisata Therapeutics	N/A	-116.08%	-90.55%

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lisata Therapeutics beats Biorestorative Therapies on 9 of the 14 factors compared between the two stocks.

How does Biorestorative Therapies compare to NeuroSense Therapeutics?

Biorestorative Therapies (NASDAQ:BRTX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

NeuroSense Therapeutics has a consensus price target of $170.00, suggesting a potential upside of 2,197.30%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

NeuroSense Therapeutics has lower revenue, but higher earnings than Biorestorative Therapies. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	9.62	-$14.24M	-$21.40	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A

In the previous week, Biorestorative Therapies had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 3 mentions for Biorestorative Therapies and 2 mentions for NeuroSense Therapeutics. Biorestorative Therapies' average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
NeuroSense Therapeutics	Neutral

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Biorestorative Therapies has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

NeuroSense Therapeutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. NeuroSense Therapeutics' return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
NeuroSense Therapeutics	N/A	N/A	N/A

Summary

NeuroSense Therapeutics beats Biorestorative Therapies on 11 of the 15 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRTX vs. The Competition

Export

Metric	Biorestorative Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.52M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.12	14.00	274.40	25.76
Price / Sales	9.62	1,342.46	688.47	106.32
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.26	15.46	10.52	6.34
Net Income	-$14.24M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-6.69%	-1.96%	-0.94%	-0.16%
1 Month Performance	-43.60%	-8.13%	-4.24%	-4.07%
1 Year Performance	-91.34%	32.15%	16.39%	5.97%

Biorestorative Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRTX Biorestorative Therapies	0.9408 of 5 stars	$2.51 -3.5%	N/A	-91.3%	$3.52M	$360K	N/A	14	Positive News Short Interest Decrease Gap Up
PLUR Pluri	0.6334 of 5 stars	$1.14 -2.9%	N/A	-76.6%	$14.49M	$1.02M	N/A	150
SYBX Synlogic	0.3996 of 5 stars	$1.17 flat	N/A	-33.1%	$14.33M	$8K	N/A	80	Positive News
HIND Vyome	1.9622 of 5 stars	$1.95 -3.0%	$9.25 +374.4%	-62.3%	$14.11M	$320K	N/A	50	Analyst Revision
LSTA Lisata Therapeutics	1.0089 of 5 stars	$1.47 -4.5%	N/A	-36.2%	$13.88M	$170K	N/A	30	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biorestorative Therapies (BRTX) Competitors

BRTX vs. PLUR, SYBX, HIND, LSTA, and NRSN

How does Biorestorative Therapies compare to Pluri?

Summary

How does Biorestorative Therapies compare to Synlogic?

Summary

How does Biorestorative Therapies compare to Vyome?

Summary

How does Biorestorative Therapies compare to Lisata Therapeutics?

Summary

How does Biorestorative Therapies compare to NeuroSense Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biorestorative Therapies (BRTX) Competitors

BRTX vs. PLUR, SYBX, HIND, LSTA, and NRSN

How does Biorestorative Therapies compare to Pluri?

Do institutionals & insiders believe in PLUR or BRTX?

Which has more risk & volatility, PLUR or BRTX?

Does the media prefer PLUR or BRTX?

Is PLUR or BRTX more profitable?

Do analysts rate PLUR or BRTX?

Which has stronger valuation & earnings, PLUR or BRTX?

Summary

How does Biorestorative Therapies compare to Synlogic?

Which has better earnings and valuation, SYBX or BRTX?

Which has more volatility & risk, SYBX or BRTX?

Do analysts prefer SYBX or BRTX?

Does the media prefer SYBX or BRTX?

Is SYBX or BRTX more profitable?

Do insiders and institutionals have more ownership in SYBX or BRTX?

Summary

How does Biorestorative Therapies compare to Vyome?

Which has preferable earnings and valuation, BRTX or HIND?

Do analysts prefer BRTX or HIND?

Which has more volatility & risk, BRTX or HIND?

Do insiders and institutionals have more ownership in BRTX or HIND?

Does the media favor BRTX or HIND?

Is BRTX or HIND more profitable?

Summary

How does Biorestorative Therapies compare to Lisata Therapeutics?

Which has more volatility and risk, BRTX or LSTA?

Does the media refer more to BRTX or LSTA?

Do analysts prefer BRTX or LSTA?

Which has stronger valuation & earnings, BRTX or LSTA?

Is BRTX or LSTA more profitable?

Do insiders & institutionals hold more shares of BRTX or LSTA?

Summary

How does Biorestorative Therapies compare to NeuroSense Therapeutics?

Do analysts rate BRTX or NRSN?

Which has better valuation and earnings, BRTX or NRSN?

Does the media favor BRTX or NRSN?

Do insiders & institutionals hold more shares of BRTX or NRSN?

Which has more risk and volatility, BRTX or NRSN?

Is BRTX or NRSN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools